

## **UTILITY PATENT APPLICATION TRANSMITTAL**

nal applications under 37 CFR §1.53(b))

· 8		(only for r	new non-provisior
	Commissioner of Box Patent Applic Washington, D.C Sir:	cation	
	Transmitted here under 37 CFR 1.53(		ling is the paten
	AVENTIS DOCKI	ET NO.:	FI5028US NP

nt application

**INVENTORS: Jean-Rene Authelin et al** MILLING PROCESS FOR THE TITLE:

PRODUCTION OF FINELY MILLED

**MEDICINAL SUBSTANCES** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231,

OII .		
June 1, 2001		
Date of Deposit	0	
Some Shen	<u> </u>	
Signature	-26	■,
EL816575891 US	က္ကထာ	.==
Express Mail No.		
	~~	
	50	
	ည	
	ห	

## **APPLICATION ELEMENTS**

1.	$\boxtimes$	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)			
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	9	
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	0	
4.	Oath a.	or Declaration  Newly unexecuted	Total Pages	2	
	b.	Copy from a prior application (37 CFR § 1.63(d))  (for continuation/divisional with Box 16 completed)			
		i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).			
5.		Microfiche Computer Program (Appendix)			
6.		eotide and/or Amino Acid Sequence Submission olicable, all necessary)  Computer Readable Copy  Paper Copy (identical to computer copy)  Statement verifying identity of above copi			

	If a CONTINUING Application, check appropriate box, and supply the requisite information:  Continuation Divisional Continuation-in-part of prior application no: PCT/GB99/04047, filed December 1, 1999,  Examiner, Group/Art Unit  (The cross reference has been/will be inserted on page one of the specification).
$\boxtimes$	This application claims the benefit of GB 9826286.8 filed December 1, 1998. (The cross reference has been/will be inserted on page one of the specification).
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prio application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
ACC	COMPANYING APPLICATION PARTS
7.	Assignment Papers (cover sheet & document(s))
8.	37 CFR §3.73(b) Statement Power of (when there is an assignee) Attorney
9.	English Translation Document (if applicable)
10.	☐ Information Disclosure ☐ Copies of IDS
	Statement (IDS)/PTO-1449 Citations
11.	Preliminary Amendment
12.	Return Receipt Postcard (MPEP 503)  (Should be specifically itemized)
13:	*Small Entity Statement(s) Statement filed in prior application,
.0.	(PTO/SB/09-12) Status still proper and desired
14.	Certified Copy of Priority Document(s)
15	(if foreign priority is claimed)
15.	Other: EFS Print
COF	RRESPONDENCE ADDRESS
	005487
$\boxtimes$	Customer Number or Bar Code Label
	(Insert Customer No. or Attach bar code label here)
	In DIT
	Ronald G. Ort, Reg. No. 26,969
<b>A</b>	Attorney/Agent for Applicant
Ave	ntis Pharmaceuticals Inc.

Patent Department

Route #202-206 / P.O. Box 6800

Mail Code: EMC-G1

Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

Aventis Docket No. FI5028US NP

PTO/SB/17 (11-00)
Appro use through 10/31/2002. OMB 0651-0032

Patent and Trademe office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) 710

Complete if Known			
Application Number	TBD		
Filing Date	Concurrently herewith		
First Named Inventor	Jean-Rene Authelin et al		
Examiner Name	TBD		
Group / Art Unit	ТВО		
Attorney Docket No.	FI5028US-NP		

METHOD OF PAYMENT		FEE CALCULATION (continued)					
The Commissioner is hereby auth indicated fees and credit any over	· .	3. A	DITION Large	NAL FI	E <b>ES</b> Small		
Deposit	i		Entity	_	Entity		
Account Number 18-198	2	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Deposit Account Name  Aventis Pharmaceutics	als Products Inc.	105	130	205	65	Surcharge - late filing fee or oath	
Charge Any Additional Fee Requir Under 37 CFR 1.16 and 1.17	ed	127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
Applicant claims small entity status See 37 CFR 1.27	s.	139	130	139	130	Non-English Specification	
2. Payment Enclosed:		147	2,520	147	2,520	For filing a request for reexamination	
	ey Order	112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION	ON	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE		115	110	215	55	Extension for reply within first month	
Large Entity Small Entity Fee Fee Fee Fee D	escription Fee	116	390	216	195	Extension for reply within second month	
Code (\$) Code (\$) 101 710 201 355 Utility	filing fee 710	117	890	217	445	Extension for reply within third month	
4	filing fee 710 n filing Fee	117	1,390	217	695	Extension for reply within fourth month	-
## · · · ·	filing fee	128	1,890	228	945	Extension for reply within fifth month	
. E	ue filing fee	119	310	219	155	Notice of Appeal	
	sional filing	120	310	220	155	Filing a brief in support of an appeal	
i –	(\$)710	121	270	221	135	Request for oral hearing	
2. EXTRA CLAIM FEES		138	1,510	138	1,510	Petition to institute a public use proceeding	
Extra Claims	Fee from Fee below Paid	140	110	240	55	Petition to revive - unavoidable	
Total Claims 16 -20**= 0 x	= 0	141	1,240	241	620	Petition to revive - unintentional	
Independent 2 - 3**= 0 x	= 0	142	1,240	242	620	Utility issue fee (or reissue)	
Claims		143	440	243	220	Design issue fee	
Multiple Dependent	= 0	144	600	244	300	Plant issue fee	
Large Entity Small Entity Fee Fee Fee Fee		122 123	130 50	122 123	130 50	Petitions to the Commissioner Petitions related to provisional applications	
	Description as in excess of 20	126	180	126	180	Submission of Information Disclosure Stmt	
102 80 202 40 Indep of 3	endent claims in excess	581	40	581	40	Recording each patent assignment per property (times number of properties)	
	ole dependent claim, if	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
109 80 209 40 **Reis	ssue independent ms over original patent	149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	
110 18 210 9 **Reis	ssue claims in excess of and over original patent	179	710	279	355	Request for Continued Examination (RCE)	
		169	900	169	900	Request for expedited examination of a design application	
SUBTOTAL (2)	(\$)0	Other fee	e (specify)				I
**or number previously paid, if greater; For Rei	issues, see above	*Reduce	d by Basic	Filing Fe	e Paid	SUBTOTAL (3) (\$)	

SUBMITTED BY

Name (Print/Type) Ronald/G. Ort

Registration No. (Attorney/Agent)

Date

Complete (If applicable)

Complete (If applicable)

Print/Type) Ronald/G. Ort

Date June 1, 2001

WARNING:Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.